Lyell Immunopharma financials
$9.63−1.13%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 |
|---|---|---|---|---|---|
| Revenue | $36.0K | $61.0K | $130.0K | $84.7M | $10.7M |
| Gross profit | $36.0K | $61.0K | $130.0K | $84.7M | $10.7M |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating income | -$271.5M | -$362.1M | -$249.8M | -$187.1M | -$214.8M |
| Net income | -$274.4M | -$343.0M | -$234.6M | -$183.1M | -$250.2M |
| Net margin | −762355.6% | −562285.2% | −180486.2% | −216.2% | −2349.5% |
| Diluted EPS | $-16.06 | $-26.23 | $-18.70 | $-14.80 | $-36.80 |
| EBITDA | -$192.2M | -$204.0M | -$229.5M | -$169.0M | -$201.2M |
| Operating cash flow | -$150.0M | -$162.4M | -$163.7M | -$169.6M | -$126.2M |
| Free cash flow | -$150.8M | -$162.9M | -$166.4M | -$193.8M | -$191.8M |
| Diluted shares | 17.1M | 13.1M | 12.5M | 12.4M | 6.8M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|
| Cash & equivalents | $60.2M | $105.6M | $145.6M | $123.6M | $293.8M |
| Short-term investments | $187.0M | $264.9M | $400.6M | $516.6M | $321.0M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $340.1M | $490.9M | $750.0M | $937.6M | $1.13B |
| Total liabilities | $91.8M | $108.0M | $95.1M | $104.3M | $197.6M |
| Shareholders' equity | $248.2M | $382.8M | $655.0M | $833.3M | $929.8M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology